Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Melanoma 13Carcinoma, Squamous Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

pembrolizumab 15avelumab 12Nivolumab 9atezolizumab 5Cyclophosphamide 5fludarabine 4Interleukin-2 4ALT-803 4durvalumab 3cemiplimab 3aldesleukin 3Ipilimumab 3domatinostat 2budigalimab 2Paclitaxel 2Docetaxel 2Bevacizumab 2zimberelimab 1venetoclax 1talimogene laherparepvec 1rovalpituzumab tesirine 1regorafenib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lorvotuzumab mertansine 1glucopyranosyl lipid-A 1epacadostat 1efineptakin alfa 1daromun 1bempegaldesleukin 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Merkel Cell × talimogene laherparepvec × Clear all
NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Pfizer

Phase 1 Terminated
56 enrolled
BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡